About ChinaAMC Hang Seng Hong Kong-Listed Biotech Index ETF Units A

159892 invests in stocks. The fund's major sectors are Health Technology, with 82.50% stocks, and Distribution Services, with 3.38% of the basket. The assets are mostly located in the Asia region.

159892 top holdings are Innovent Biologics, Inc. and Wuxi Biologics (Cayman) Inc., occupying 10.27% and 8.79% of the portfolio correspondingly.

159892 assets under management is ‪6.00 B‬ CNY. It's fallen 0.56% over the last month.

159892 fund flows account for ‪−267.03 M‬ CNY (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.

No, 159892 doesn't pay dividends to its holders.

159892 expense ratio is 0.65% meaning you'd have to pay 0.65% of your investment to help manage the fund.

159892 follows the Hang Seng Biotech Index - HKD - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.

159892 invests in stocks.

159892 price has fallen by −8.07% over the last month, and its yearly performance shows a 69.47% increase. See more dynamics on 159892 price chart.
NAV returns, another gauge of an ETF dynamics, have risen by −8.97% over the last month, have fallen by −8.97% over the last month, showed a 1.89% increase in three-month performance and has increased by 71.61% in a year.